For example, AdvanTIG-203 shows that tislelizumab combined with TIGIT monoclonal antibody Ociperlimab has better advantages compared with placebo in the treatment of PD-L1 positive esophageal squamous cell carcinoma. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.